Home › Oral Cancer › Michigan › Livonia
Oral Cancer clinical trials in Livonia, MI
3 studies for Oral Cancer are looking for participants at sites in and around Livonia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
RecruitingPhase 3
- Trinity Health Saint Mary Mercy Livonia Hospital, Livonia
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- Trinity Health Saint Mary Mercy Livonia Hospital, Livonia
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecruitingPhase 2
- Trinity Health Saint Mary Mercy Livonia Hospital, Livonia
About Oral Cancer
Oral cancer can form in the mouth or throat but usually begins in the tongue and floor of the mouth. Read about the common oral cancer symptoms.
More about Oral Cancer on MedlinePlus
Oral Cancer trials in other cities
- Atlanta, GA9 studies
- St. Louis, MO8 studies
- Chicago, IL8 studies
- New York City, NY8 studies
- Durham, NC7 studies
- Houston, TX7 studies
- Ann Arbor, MI7 studies
- Kansas City, MO7 studies
- Portland, OR7 studies
- Pittsburgh, PA7 studies
- Milwaukee, WI7 studies
- Richmond, VA7 studies
Other studies in Livonia
- Lung Cancer10 studies
- Non-Small Cell Lung Cancer8 studies
- Acute Myeloid Leukemia7 studies
- Prostate Cancer7 studies
- Colorectal Cancer6 studies
- Kidney Cancer (Renal Cell Carcinoma)5 studies
- Ovarian Cancer4 studies
- Bladder Cancer4 studies
- Breast Cancer4 studies
- Multiple Myeloma3 studies
- Esophageal Cancer3 studies
- Stomach Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.